Trial · NCT07144657
Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
NCT07144657, Phase 2, Not yet recruiting, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma. Trials, record NCT07144657. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07144657
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma
- NCT number
- NCT07144657
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- MALT Lymphoma of Stomach
- Interventions
- Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole
- First posted
- 2025-08-27
- Last updated
- 2025-08-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The treatment efficacies of frontline antibiotics treatment for Helicobacter pylori-negative gastric MALT lymphoma | 2 years | 1\. The overall response rate (including complete remission \[CR\] and partial remission \[PR\]) for frontline antibiotics treatment (two weeks of quadruple HPE regimens followed by 4 weeks of clarithromycin) in stage IE/IIE1 HP-negative gastric MALT lymphoma. 2 The median time to CR or PR after completion of antibiotics and duration of CR or PR. 3 The overall response rate (including CR and PR) for immune treatment (CAMC) in antibiotics-unresponsive HP-negative gastric MALT lymphoma |
| Secondary | The clinical outcomes of HP-negative gastric MALT lymphoma after antibiotics treatment and low-dose cyclophosphamide and clarithromycin | 3 years | 1. The event-free survival and overall survival of all patients. 2. The biological markers in predicting the antibiotic-responsiveness of HP- negative gastric MALT lymphoma 3. The biological markers in predicting the CAMC-responsive of antibiotics- unresponsive HP-negative gastric MALT lymphoma 4. The assessment of adverse effects of CAMC immune regimen. 5. The identification of microbiota, including non-Helicobacter pylori Helicobacter (NHPH), the other bacteria, or gut microbiota that contributes to the lymphomagenesis of HP-negative gastric MALT lymphoma |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07144657
GET https://conductscience.org/api/trials/v1/NCT07144657/registered